The discovery of potent and selective pyridopyrimidin-7-one based inhibitors of B-RafV600E kinase

Herein we describe the discovery of a novel series of ATP competitive B-Raf inhibitors via structure based drug design (SBDD). These pyridopyrimidin-7-one based inhibitors exhibit both excellent cellular potency and striking B-Raf selectivity. Optimization led to the identification of compound 17, a potent, selective and orally available agent with excellent pharmacokinetic properties and robust tumor growth inhibition in xenograft studies.

Graphical abstractFigure optionsDownload full-size imageDownload as PowerPoint slide